Claudio Cavazza, Composition for the Prevention and Treatment of Osteoporosis due to Menopause Syndrome (2002), US Patent 6,335,038, column 3
Some users report enhanced results from subcutaneous injection providing systemic levels while oral dosing delivers local esophageal exposure
In selected individuals who manifest the above symptoms or disorders and who have not responded adequately to standard therapies, a trial of L-carnitine may be considered
Intraperitoneal melatonin is not neuroprotective in the g93asod1 transgenic mouse model of familial als and may exacerbate neurodegeneration
Diagnosis and classification of pernicious anemia
[59] Agarwal A, Aponte-Mellado A, Premkumar BJ, Shaman A, Gupta S